(ZEN) ZEN Graphene Solutions - Ratings and Ratios

Zentek Ltd. (formerly ZEN Graphene Solutions Ltd.) is a Canadian company specializing in the research, development, and commercialization of graphene and related nanomaterials. Headquartered in Guelph, Canada, the company operates across multiple industries, leveraging the unique properties of graphene to enhance product performance. Its product portfolio includes ZenGUARD™, a graphene-based antimicrobial coating designed for applications such as surgical masks, HVAC filters, and personal protective equipment (PPE). Additionally, Zentek develops rapid detection point-of-care diagnostics and pharmaceutical products utilizing graphene-based compounds.

Zentek is also advancing graphene oxide and graphene synthesis technologies, focusing on scalability and cost-effectiveness. The company holds a 100% interest in the Albany graphite project in Northern Ontario, a strategic asset for sourcing high-quality graphite, a key precursor for graphene production. Since its incorporation in 2008, Zentek has positioned itself as a leader in the graphene space, with a strong emphasis on innovation and commercialization. The company rebranded from ZEN Graphene Solutions Ltd. to Zentek Ltd. in October 2021 to reflect its expanded focus and growth strategy.

Ticker Symbol: ZEN
Exchange: V
Type: common stock
Country Origin: Canada
GICS Sub Industry: Health Care Equipment

Average Volume 20d: 28542
Last Price: 1.40
SMA 20: 1.50
SMA 50: 1.49
SMA 200: 1.36
ATR: 0.11

Market Cap: 177.95M CAD
P/E: 0.00
P/E Forward: 0.00
P/B: 9.14
P/S: 2290.11
RoE: -65.80

3-Month Forecast:
Based on , ZEN is currently trading below its SMA 20 and SMA 50, indicating bearish momentum. The SMA 200 is lower, suggesting a longer-term downtrend. With an ATR of 0.11, volatility is relatively low, but the average volume of 28,542 shares indicates limited market participation.

From a perspective, Zenteks high P/S ratio of 2290.11 reflects its speculative nature as a pre-revenue company. The negative RoE of -65.80 highlights ongoing financial losses, which could weigh on investor sentiment. The P/B ratio of 9.14 suggests the market expects significant growth, but this is contingent on the company achieving profitability and commercial success.